- Home
- ATYR vs TCRX Comparison
ATYR vs TCRX Comparison
Compare ATYR & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATYR | TCRX |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.2M | 49.4M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ATYR | TCRX |
|---|---|---|
| Price | $0.18 | $0.24 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 5 |
| Target Price | ★ $2.86 | $1.00 |
| AVG Volume (30 Days) | ★ 3.0M | 678.6K |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 6.98 | ★ 12.28 |
| EPS | ★ N/A | N/A |
| Revenue | $190,000.00 | ★ $10,325,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 266.65 |
| 52 Week Low | $0.18 | $0.20 |
| 52 Week High | $1.11 | $2.57 |
Technical Indicators
Market Signals| Indicator | ATYR | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 18.11 | 28.60 |
| Support Level | N/A | N/A |
| Resistance Level | $0.59 | $0.37 |
| Average True Range (ATR) | 0.02 | 0.03 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 8.25 | 23.63 |
Price Performance
Historical ComparisonAbout ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.